Insights
Insights From Our Experts
Articles
ICER’s Unsupported Price Increase Assessment
Posted on December 23, 201912/23/19
In October 2019, the Institute of Clinical and Economic Review (ICER) released their first annual report on Unsupported Price Increases of prescription drugs in the United States. The report takes a systematic approach to determine whether…
Trends Disrupting Life Sciences in 2020
From the commercialization of digital medicines to the evolution of value-driven healthcare – our thought leaders deliver insight on the trends impacting the life science industry that will continue to shape our thinking well in 2020…
How to Maximize the Value of New Advances in Oncology
Today we have access to more data, from more sources than we could ever dream possible. Living in a digital world, we increasingly need the ability to efficiently and effectively process this data for insights and…
U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines
According to a recent study from Health Strategies Insights by EVERSANA, 89% of U.S. physicians disagree with Germany’s determinations of the clinical benefit of innovative diabetes medicines. Learn more about our Market Access products & capabilities!…
“Ask the Expert” About Digital Therapeutics
The promise of digital health – from wearables to mobile health apps – could revolutionize healthcare by improving adherence, reducing costs, and making treatments more personalized. Mike Ryan shares insight on the opportunity to set a…
Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem
Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient…
Strategies to Ensure Market Success of a Rare Disease Product Launch
Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider…
How to Demonstrate Value to Providers, Payers & Patients
Fact: Primary stakeholders – providers, patients and payers – have greater expectations than ever before. To ensure success at every stage of the product life cycle, it’s imperative to deploy a sophisticated, clinically oriented and data-driven…
More Data, More Problems, More Potential
As the healthcare industry shifts from volume-based care to a value-based reimbursement structure, data analytics will be critical in shaping the future of the pharmaceutical industry. More so than perhaps any recent industry trend, value base…
Ask the Expert – Digital Therapeutics
From reimbursement strategies, distribution, dispensing, patient engagement and adherence programs, EVERSANA offers integrated solutions to alleviate the barriers facing the adoption of digital therapeutics. Mike Ryan, Executive Vice President of Europe and Asia Pacific, discusses how…